R
Richard D. Carvajal
Researcher at Columbia University
Publications - 332
Citations - 28287
Richard D. Carvajal is an academic researcher from Columbia University. The author has contributed to research in topics: Melanoma & Medicine. The author has an hindex of 54, co-authored 282 publications receiving 23524 citations. Previous affiliations of Richard D. Carvajal include Cornell University & Kettering University.
Papers
More filters
Journal ArticleDOI
Novel Targets for the Treatment of Melanoma.
TL;DR: While strides have been made in the treatment of advanced melanoma, further research is needed to identify alternative immune and molecular targets in order to overcome resistance and achieve better clinical outcomes.
Journal ArticleDOI
The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma.
Jacob D. Soumerai,Andrew D. Zelenetz,Craig H. Moskowitz,M. Lia Palomba,Paul A. Hamlin,Ariela Noy,David J. Straus,Alison J. Moskowitz,Anas Younes,Matthew J. Matasar,Steven M. Horwitz,Carol S. Portlock,Jason A. Konner,Mrinal M. Gounder,David M. Hyman,Martin H. Voss,Matthew G. Fury,Devika Gajria,Richard D. Carvajal,Alan L. Ho,Jan H. Beumer,Brian F. Kiesel,Zhigang Zhang,Alice P. Chen,Richard F. Little,Christine Jarjies,Thu Oanh Dang,Nishant Mishra,John F. Gerecitano +28 more
TL;DR: VBR had preliminary clinical activity in patients with B-cell lymphoma, which warrants further investigation in a phase II trial, and veliparib clearance was slightly lower than previously reported.
A Nonrandomized, Phase II Study of Sequential Irinotecan and Flavopiridol in Patients With Advanced Hepatocellular Carcinoma.
Celina Ang,Eileen M. O'Reilly,Richard D. Carvajal,Marinela Capanu,Mithat Gonen,Laurence Doyle,Ronald Ghossein,Lawrence H. Schwartz,G. Jacobs,Jennifer Ma,Gary K. Schwartz,Ghassan K. Abou-Alfa +11 more
TL;DR: It is possible that the presence of wild-type p53 is necessary but not sufficient to predict response in HCC, and the sequential combination of irinotecan and flavopiridol are ineffective and poorly tolerated in patients with advanced HCC.
Journal ArticleDOI
Patient perspectives on ipilimumab across the melanoma treatment trajectory
Elyse Shuk,Alexander N. Shoushtari,Alexander N. Shoushtari,Jason J. Luke,Michael A. Postow,Michael A. Postow,Maggie Callahan,Maggie Callahan,James J. Harding,James J. Harding,Katherine G. Roth,Marisa Flavin,Adrian Granobles,Jana Christian,Geoffrey S. Gold,Maria Schoenhammer,Mallorie Gordon,Nicholas Cimaglia,Robert Dyson,Noah Goodman-Davis,Marta N. Colgan,Itisha S. Jefferson,Rodrigo Ramella Munhoz,Sandra P. D'Angelo,Sandra P. D'Angelo,Jedd D. Wolchok,Jedd D. Wolchok,Paul B. Chapman,Paul B. Chapman,Ping Chi,Ping Chi,Richard D. Carvajal,Jennifer L. Hay +32 more
TL;DR: Patients generally regarded ipilimumab positively despite the risk of unique toxicities and potential for delayed therapeutic responses; however, those with progression expressed uncertainty regarding whether taking ipILimumab was worthwhile.
Journal ArticleDOI
Combination checkpoint blockade for metastatic cutaneous malignancies in kidney transplant recipients
Megan H. Trager,Shana M. Coley,Geoffrey K. Dube,Shaheer Khan,Matthew Ingham,Faramarz H. Samie,Larisa J. Geskin,Diana McDonnell,Daniel Brouder,Yvonne M. Saenger,Richard D. Carvajal +10 more
TL;DR: These cases describe the use of ipilimumab and nivolumab combination immunotherapy for cutaneous malignancies in kidney transplant recipients and highlight the potential to preserve kidney graft function while effectively treating the disease.